Details for Patent: 7,198,801

Which drugs does patent 7,198,801 protect, and when does it expire?

Patent 7,198,801 protects ELESTRIN and GELNIQUE 3% and is included in two NDAs.

This patent has fifty-five patent family members in twenty countries.

Summary for Patent: 7,198,801

Title:	Formulations for transdermal or transmucosal application
Abstract:	The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s):	Carrara; Dario Norberto R. (Oberwil, CH), Grenier; Arnaud (Steinbrunn le Haut, FR), Besse; Celine (Saint Louis, FR), Simes; Stephen M. (Long Grove, IL), Lehman; Leah M. (Green Oaks, IL)
Assignee:	Antares Pharma IPL AG (Zug, CH)
Application Number:	10/798,161
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,198,801
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,198,801

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Speciality Lp	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006		RX	Yes	Yes			Y
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 7,198,801

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP00/07533	Aug 03, 2000

International Family Members for US Patent 7,198,801

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	030312
Austria	355854
Austria	356636
Austria	485837